Effects of the strong CYP3A4 and P-glycoprotein inhibitor itraconazole on the pharmacokinetics of oral and intranasal zavegepant

被引：0
|
作者：
Bhardwaj, R. [1 ]
Malatesta, J. K. [2 ]
Stringfellow, J. [3 ]
Madonia, J. [4 ]
Anderson, M. [4 ]
Stock, D. A. [4 ]
Morris, B. A. [4 ]
Coric, V [5 ]
Croop, R. [5 ]
Bertz, R. [4 ]
机构：
[1] Certara Strateg Consulting, Integrated Drug Dev, Princeton, NJ USA
[2] Certara USA, Princeton, NJ USA
[3] Navitas Data Sci, Pottstown, PA USA
[4] Biohaven Pharmaceut, New Haven, CT USA
[5] Biohaven Pharmaceut Holding Co Ltd, New Haven, CT USA
来源：
HEADACHE | 2022年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-163
引用
收藏
页码：140 / 141
页数：2
相关论文
共 50 条
  • [21] Itraconazole, a P-Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin-Inhibiting Effect of Aliskiren
    Tapaninen, Tuija
    Backman, Janne T.
    Kurkinen, Kaisa J.
    Neuvonen, Pertti J.
    Niemi, Mikko
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (03): : 359 - 367
  • [22] Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein
    Cho, Young-Ah
    Choi, Jun-Shik
    Burm, Jin-Pil
    PHARMACOLOGICAL REPORTS, 2011, 63 (04) : 1066 - 1073
  • [23] Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein
    Young-Ah Cho
    Jun-Shik Choi
    Jin-Pil Burm
    Pharmacological Reports, 2011, 63 : 1066 - 1073
  • [24] Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein
    Egashira, K
    Ohtani, H
    Itoh, S
    Koyabu, N
    Tsujimoto, M
    Murakami, H
    Sawada, Y
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (08) : 828 - 833
  • [25] The barrier function of CYP3A4 and P-glycoprotein in the small bowel
    Watkins, PB
    ADVANCED DRUG DELIVERY REVIEWS, 1997, 27 (2-3) : 161 - 170
  • [26] Effects of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics of a single oral dose of tamsulosin
    Troost, J.
    Tatami, S.
    Tsuda, Y.
    Mattheus, M.
    Mehlburger, L.
    Michel, M. C.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (02) : 305 - 305
  • [27] The Pharmacokinetics of Darexaban (YM150), an Oral Direct Factor Xa Inhibitor, Are Not Affected by Ketoconazole, a Strong Inhibitor of CYP3A and P-glycoprotein
    Groenendaal, Dorien
    Strabach, Gregory
    Garcia-Hernandez, Alberto
    Kadokura, Takeshi
    Heeringa, Marten
    Mol, Roelof
    Eltink, Charlotte
    Onkels, Hartmut
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (03): : 194 - 201
  • [28] P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability
    Martinez-Chavez, Alejandra
    van Hoppe, Stephanie
    Rosing, Hilde
    Lebre, Maria C.
    Tibben, Matthijs
    Beijnen, Jos H.
    Schinkel, Alfred H.
    MOLECULAR PHARMACEUTICS, 2019, 16 (09) : 3842 - 3852
  • [29] Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein
    Shimizu, M
    Uno, T
    Sugawara, K
    Tateishi, T
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (05) : 538 - 544
  • [30] Effect of herbal bioenhancer (naringenin) on the pharmacokinetics of diltiazem in rats via CYP3A4 and P-glycoprotein inhibition
    Pingili, Ravindra Babu
    Vemulapalli, Sridhar
    Mullapudi, Surya Sandeep
    Chinnala, Krishna Mohan
    Kilaru, Naveen Babu
    ANNALS OF PHYTOMEDICINE-AN INTERNATIONAL JOURNAL, 2022, 11 (02): : 654 - 660
12345